You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Moodys
Express Scripts
McKinsey
AstraZeneca

Last Updated: July 9, 2020

DrugPatentWatch Database Preview

Patent: 8,431,380

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,431,380
Title:Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Inventor(s): Bookbinder; Louis (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee: Halozyme, Inc. (San Diego, CA)
Application Number:12/378,984
Patent Claims:see list of patent claims

Details for Patent 8,431,380

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 001 2005-12-02   Start Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX company
Akorn Inc HYDASE hyaluronidase INJECTABLE;INJECTION 021716 001 2005-10-25   Start Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 DISCN search
Amphastar Pharm AMPHADASE hyaluronidase INJECTABLE;INJECTION 021665 001 2005-11-03   Start Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX search
Bausch And Lomb VITRASE hyaluronidase INJECTABLE;INJECTION 021640 002 2004-12-21   Start Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX search
Bausch And Lomb VITRASE hyaluronidase INJECTABLE;INJECTION 021640 001 2004-12-21   Start Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Moodys
McKinsey
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.